Diabetic Retinopathy Clinical Trials

21 studies are recruiting for diabetic retinopathy in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

   Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina). Over time, this damage can lead to vision problems and even blindness if not treated. This study will assess surabgene lomp…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Barnet Dulaney Perkins Eye Center - Mesa /ID# 283000, Mesa, Arizona

   Locations

   40 in total

   Run by

   AbbVie

   See if you can join NCT07592273 on ClinicalTrials.gov

2. A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

   This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Florida Retina Institute, Jacksonville, Florida

   Locations

   90 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06321302 on ClinicalTrials.gov

3. National Eye Institute Biorepository for Retinal Diseases

   Background: - To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time. They also want to study body tissues and blood to understand the nature of eye disease. Studying genes…

   Stage

   Not phased

   Ages

   2 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Eye Institute (NEI)

   See if you can join NCT01496625 on ClinicalTrials.gov

4. Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

   This study proposes to carefully examine the hypothesis that human inducible pluripotent stem cells (iPSCs) can be effectively employed as a future therapeutic option for individuals with diabetic retinopathy and macular ischemia. iPSCs will be generated from the peripheral blood cells of subjects …

   Stage

   Not phased

   Ages

   21 to 98

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT03403699 on ClinicalTrials.gov

5. A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

   Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for ev…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Associated Retina Consultants, Ltd ( Site 0084), Gilbert, Arizona

   Locations

   33 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07705555 on ClinicalTrials.gov

6. A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

   Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for ev…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Retina Group of New England ( Site 0101), Waterford, Connecticut

   Locations

   19 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07705607 on ClinicalTrials.gov

7. Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes

   This pragmatic clinical trial is being conducted to test the effectiveness of AI-BRIDGE (Artificial Intelligence-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education), in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 8 prima…

   Stage

   Not phased

   Ages

   22 and older

   Site

   UW School of Medicine and Public Health, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT06763952 on ClinicalTrials.gov

8. Intraoperative OCT Guidance of Intraocular Surgery II

   The overall five-year goals of the project are to develop novel technology to provide actionable new information through provision of live volumetric imaging during surgery, improving surgical practice and outcomes. The investigators believe this technology will enable novel ophthalmic and other mi…

   Stage

   Not phased

   Ages

   0 and older

   Site

   Duke University Eye Center, Durham, North Carolina

   Run by

   Duke University

   See if you can join NCT03713268 on ClinicalTrials.gov

9. Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION

   This trial will study the safety and efficacy of intranasal delivery of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of non-arteritic ischemic optic neuropathy

   Stage

   Phase 1

   Ages

   Any age

   Site

   Prodromos Stem Cell Institute, Naples, Florida

   Locations

   2 in total

   Run by

   The Foundation for Orthopaedics and Regenerative Medicine

   See if you can join NCT05147701 on ClinicalTrials.gov

10. A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

    This study will assess the safety, tolerability, and pharmacokinetics (PK) of intravitreal (IVT) injections of RO7663498 in participants with diabetic retinopathy (DR).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Global Research Management, Glendale, California

    Locations

    4 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT07588100 on ClinicalTrials.gov

11. Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

    Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X r…

    Stage

    Not phased

    Ages

    21 to 98

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT03403686 on ClinicalTrials.gov

12. Corticosteroid for Diabetic Macular Edema (DME) Study

    Our current goals include confirming inflammation mediators are biomarkers of DR and DME The Aim of this project is to measure aqueous PGE2 and inflammatory cytokines before and after treatment of DME with intravitreal corticosteroid injections. We want to continue the study for one more year as ou…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Vanderbilt Eye Institute, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT07843849 on ClinicalTrials.gov

13. Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities

    An online survey (n=1,500) and 4 focus groups will be conducted with Latinx patients with diabetes (n=20) to obtain preliminary data regarding whether and how patient and clinician video testimonial interventions (n=6) increase eye health literacy and trust in healthcare.

    Stage

    Not phased

    Ages

    18 and older

    Site

    UW Hospital and Clinics, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT06257082 on ClinicalTrials.gov

14. Clinical Applications of Advanced Ophthalmic Imaging

    The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls. There are two phases in this study. The firs…

    Stage

    Not phased

    Ages

    18 to 99

    Site

    Bascom Palmer Eye Institute, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT03135327 on ClinicalTrials.gov

15. Biomarker of Diabetic Retinopathy

    Diabetic retinopathy (DR) is a complication of diabetes in which blood vessels supplying blood to the back of the eye (retina) are dysfunctional. This can lead to an improper supply of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood vessels in response to th…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Spring Mill Clinic, Carmel, Indiana

    Locations

    3 in total

    Run by

    Indiana University

    See if you can join NCT05079399 on ClinicalTrials.gov

16. Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

    This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of d…

    Stage

    Not phased

    Ages

    18 to 99

    Site

    Wilmer Eye Institute, Baltimore, Maryland

    Run by

    Johns Hopkins University

    See if you can join NCT04505618 on ClinicalTrials.gov

17. Village-Integrated Eye Worker Trial II

    The vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early diagnosis and treatment. The leading causes of visual impairment are cataract and refractive error, followed by glaucoma, age-r…

    Stage

    Not phased

    Ages

    60 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT03752840 on ClinicalTrials.gov

18. Strategies for Improving Linkage-to-Care After Eye Disease Screening

    The goal of this randomized, parallel-group, controlled trial is to compare methods of improving linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease screening. Participants who are referred to the hospit…

    Stage

    Not phased

    Ages

    60 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT06943599 on ClinicalTrials.gov

19. Sleep, Diabetic Retinopathy and Melatonin

    This study explores the use of melatonin in patients with diabetic retinopathy

    Stage

    Phase 2

    Ages

    40 to 65

    Site

    University of Illinois at Chicago, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT04547439 on ClinicalTrials.gov

20. Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

    The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    University of Michigan Kellogg Eye Center, Ann Arbor, Michigan

    Run by

    MediBeacon

    See if you can join NCT04008121 on ClinicalTrials.gov

21. Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

    In this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of blindness in the Un…

    Stage

    Not phased

    Ages

    22 and older

    Site

    iHealthScreen Inc., Richmond Hill, New York

    Run by

    iHealthScreen Inc

    See if you can join NCT07151001 on ClinicalTrials.gov